Cold, Flu & Cough News and Research

Latest Cold, Flu & Cough News and Research

BioCryst to present data on BCX4208 for gout at ACR Scientific Meeting

BioCryst Pharmaceuticals, Inc. announced the presentation of new data related to the efficacy and safety of BCX4208 for the treatment of gout at the 74th ACR Scientific Meeting being held in Atlanta, Georgia.

9 Nov 2010

New COLD-PCR technology to detect EGFR gene mutation

Transgenomic, Inc. today announced completion of a development study of several new assays to detect genetic mutations using the Company's proprietary Co-amplification at Lower Denaturing Temperature PCR (COLD-PCR) technology in the Epidermal Growth Factor Receptor (EGFR) gene.

8 Nov 2010

Vapor rub improves sleep for children with cold symptoms

Applying a vapor rub is effective for treating children with night-time cough and congestion and improves sleep for children with cold symptoms, according to Penn State College of Medicine researchers.

8 Nov 2010

Apricus receives $733,437 grants under QTDP program

Apricus Biosciences, Inc., today announced the award of three grants totaling $733,437 under the Qualifying Therapeutic Discovery Project program for PrevOnco, RayVa and Femprox which are the Company's development programs in cancer, autoimmune/cardiovascular and female sexual dysfunction, respectively.

8 Nov 2010

FDA approves Cymbalta for treatment of chronic musculoskeletal pain

The U.S. Food and Drug Administration today approved Cymbalta (duloxetine hydrochloride) to treat chronic musculoskeletal pain, including discomfort from osteoarthritis and chronic lower back pain. Cymbalta was first used to treat major depressive disorder in 2004.

8 Nov 2010

Inviragen to present data on CHIKV vaccine at ASTMH meeting

Inviragen, a biotechnology company developing vaccines to protect against infectious diseases worldwide, together with investigators at the University of Texas Medical Branch (UTMB) and the Division of Vector Borne Diseases (DVBD) of the Centers for Disease Control and Prevention, will make an oral presentation today at the annual American Society of Tropical Medicine and Hygiene (ASTMH) meeting on preclinical results of the Company's experimental chikungunya virus (CHIKV) vaccine.

8 Nov 2010

Prestige Brands second fiscal quarter net revenue decreases 3% to $78.3 million

Prestige Brands Holdings, Inc. today announced results for the second quarter and first half of fiscal year 2011, which ended on September 30, 2010. The Company also announced the completion on November 1, 2010 of the acquisition of Blacksmith Brands, Inc., which added five over-the-counter healthcare products to its business.

4 Nov 2010

Experts develop tools to educate people about health risks associated with global travel

More than 30 million people in the United States travel to resource-limited areas of the world each year. This global mobility may contribute to the spread of infectious diseases such as influenza, measles, and meningitis and may also put individual travelers at risk for malaria, typhoid, dengue fever and hepatitis.

4 Nov 2010

Advanced Life Sciences awarded $244,479.25 grant under Qualifying Therapeutic Discovery Project

Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced that the Company has been awarded a cash grant under the Qualifying Therapeutic Discovery Project which was created by Congress as part of the Patient Protection and Affordable Care Act of 2010.

4 Nov 2010

HPV vaccine enjoys wide support from medical and public health communities

The vaccine that protects against the potentially cancer-causing human papillomavirus (HPV) enjoys wide support in the medical and public health communities. Yet state laws to require young girls to be vaccinated as a requirement for middle school attendance have aroused controversy with parents, politicians, and even medical and public health experts disagreeing about whether such laws are appropriate.

4 Nov 2010

Afinitor tablets decrease size of SEGA associated with tuberous sclerosis

The New England Journal of Medicine (NEJM) today published a study that found patients taking Afinitor (everolimus) tablets experienced a decrease in the size of their subependymal giant cell astrocytoma (SEGA), a benign brain tumor associated with tuberous sclerosis (TS).

4 Nov 2010

Cempra to present information on solithromycin antimalarial agent at Atlanta Annual Meeting

Cempra Pharmaceuticals today announced abstracts to be presented on its novel fluoroketolide antibiotic, solithromycin (CEM-101), at the American Society of Tropical Medicine and Hygiene 59th Annual Meeting, November 3 to 7 in Atlanta. The abstracts will present new information on solithromycin's antimalarial activity. Additional data will demonstrate activity against Mycobacterium leprae.

4 Nov 2010

Cocrystal receives $733,438 in grants from QTDP program

Cocrystal Discovery, Inc., a biopharmaceutical company focused on the discovery and development of novel antiviral therapeutics for the treatment of serious and chronic viral diseases, announced today that it has received $733,438 in grants from the Qualified Therapeutic Discovery Project (QTDP) administered under section 48D of the Internal Revenue Code.

4 Nov 2010

Acton submits Manufacturing Supplement to FDA for AEROSPAN Inhalation Aerosol

Acton Pharmaceuticals, Inc. today announced that it has submitted to the U.S. Food and Drug Administration (FDA), a Manufacturing Supplement to the previously approved AEROSPAN Inhalation Aerosol NDA.

4 Nov 2010

Idaho seeks FDA marketing clearance for FilmArray Respiratory Panel

Idaho Technology, Inc. (ITI) announced today that it has filed a submission with the U.S. Food and Drug Administration for 510(k) clearance to market its FilmArray Respiratory Panel (RP) as an in vitro diagnostic product for patients with symptoms of upper respiratory tract infection.

4 Nov 2010

SYMBICORT improves lung function in African American asthma patients compared to budesonide alone

AstraZeneca announced today that results from TITAN, a 12-week study of SYMBICORT® (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol in African American patients with moderate to severe persistent asthma, showed significant improvement in lung function for patients taking SYMBICORT compared with those using budesonide alone.

3 Nov 2010

Immune Network to complete patient enrollment in Phase 2b imm01 trial for tuberculosis

Immune Network Ltd. a company in the business of discovery and development of immune-based therapies, today announced that patient enrollment will be completed next week for the company's future partner Immunitor's Phase 2b imm01 trial of V5 immunotherapy in 120 patients with tuberculosis.

3 Nov 2010

Study reveals positive correlation between specialty nursing certification and workplace empowerment

Building on the body of evidence supporting a link between specialty nursing certification and workplace empowerment, a new study documents a positive association between nurses' perceptions of workplace empowerment and the proportion of nurses with specialty certification in hospital units.

3 Nov 2010

Strengthening influenza vaccination programs may help states improve coverage against pandemics

Strengthening routine influenza vaccination and health programs may help states improve their vaccination coverage against future pandemics or other health emergencies, a new study suggests.

3 Nov 2010

GenVec receives $244,479 grant under QTDP program

GenVec, Inc. announced today that it was awarded a cash grant of approximately $244,479 under the U.S. Government's Qualifying Therapeutic Discovery Project program.

3 Nov 2010